Royce & Associates LP increased its stake in Alphatec Holdings Inc (NASDAQ:ATEC) by 124.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 35,000 shares of the medical technology company’s stock after acquiring an additional 19,432 shares during the quarter. Royce & Associates LP owned approximately 0.08% of Alphatec worth $80,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Beacon Pointe Wealth Advisors LLC acquired a new stake in Alphatec during the 4th quarter worth $36,000. Raymond James Financial Services Advisors Inc. boosted its stake in Alphatec by 49.2% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock worth $67,000 after purchasing an additional 9,579 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Alphatec during the 3rd quarter worth $165,000. Dimensional Fund Advisors LP boosted its stake in Alphatec by 206.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 87,957 shares of the medical technology company’s stock worth $296,000 after purchasing an additional 59,266 shares during the last quarter. Finally, PNC Financial Services Group Inc. acquired a new stake in Alphatec during the 3rd quarter worth $548,000. 18.57% of the stock is owned by institutional investors.
Shares of ATEC stock opened at $2.92 on Friday. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.48 and a current ratio of 2.36. The stock has a market cap of $126.18 million, a PE ratio of -5.03 and a beta of 1.14. Alphatec Holdings Inc has a twelve month low of $1.18 and a twelve month high of $4.21.
Several equities research analysts have issued reports on ATEC shares. ValuEngine raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Alphatec in a research note on Monday, January 14th. Finally, Zacks Investment Research raised shares of Alphatec from a “strong sell” rating to a “hold” rating in a research report on Monday, January 14th.
In other news, EVP Kelli Mari Howell purchased 100,000 shares of the stock in a transaction dated Monday, March 11th. The shares were purchased at an average price of $2.59 per share, with a total value of $259,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Evan Bakst purchased 20,566 shares of the stock in a transaction dated Monday, March 11th. The shares were purchased at an average cost of $2.59 per share, for a total transaction of $53,265.94. Following the transaction, the director now owns 726,912 shares in the company, valued at approximately $1,882,702.08. The disclosure for this purchase can be found here. Insiders own 44.40% of the company’s stock.
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Featured Story: Derivative
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.